European Society of Cardiology (ESC) Congress 2021

After the initial and 3-month doses, twice-yearly dosing of inclisiran led to effective and sustained LDL-C* reduction in patients with and without polyvascular disease (PVD**), according to a pooled analysis of the ORION-9, ORION-10, and ORION-11 phase III trials.

Having high serum sodium levels above 142 mmol/L — which is indicative of insufficient fluid intake — is associated with a greater risk of left ventricular hypertrophy (LVH) and heart failure (HF) in later life, according to the ARIC* study presented at ESC 2021 Congress.

In individuals who were discharged following hospitalization due to COVID-19, thromboprophylaxis with the novel oral anticoagulant rivaroxaban for 35 days led to improved clinical outcomes without increased bleeding compared with no anticoagulation post-discharge, according to findings from the MICHELLE* trial.

The Amplatzer™ Amulet™ LAA* Occluder has shown superiority over the Watchman** device in terms of LAA closure and noninferiority in terms of efficacy and safety for preventing stroke in patients with nonvalvular atrial fibrillation (AF), according to findings from the AMULET IDE trial.

The NOAC* edoxaban was noninferior to VKA** for the primary composite outcome of net adverse clinical events (NACE) after a successful TAVI*** in patients with atrial fibrillation (AF), but this comes at the cost of higher major bleeding rates, according to the ENVISAGE-TAVI AF# trial — thus leaving the question on the optimal antithrombotic strategies in AF after TAVI unanswered.